# The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants

> **NCT00500305** · NA · COMPLETED · sponsor: **University of Virginia** · enrollment: 60 (actual)

## Conditions studied

- Indomethacin Therapy
- Patent Ductus Arteriosus

## Interventions

- **PROCEDURE:** Withhold standard INDO dose if BNP < 100 pg/ml

## Key facts

- **NCT ID:** NCT00500305
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00500305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00500305, "The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00500305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*